Syndecan1 is a critical mediator of macropinocytosis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains recalcitrant to all forms of cancer treatment and carries a dismal 5-year survival rate of 8%(1). Inhibition of oncogenic KRAS (hereafter KRAS*), the earliest lesion in disease development that is present in >90% of PDAC, and its signaling surrogate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Wantong, Rose, Johnathon L., Wang, Wei, Seth, Sahil, Jiang, Hong, Taguchi, Ayumu, Liu, Jintan, Yan, Liang, Kapoor, Avnish, Hou, Pingping, Chen, Ziheng, Wang, Qiuyun, Nezi, Luigi, Xu, Zhaohui, Yao, Jun, Hu, Baoli, Pettazzoni, Piergiorgio F., Ho, I Lin, Feng, Ningping, Ramamoorthy, Vandhana, Jiang, Shan, Deng, Pingna, Ma, Grace J., Den, Peter, Tan, Zhi, Zhang, Shu Xing, Wang, Huamin, Wang, Alan Y., Deem, Angela K., Fleming, Jason B., Carugo, Alessandro, Heffernan, Timothy P., Maitra, Anirban, Viale, Andrea, Ying, Haoqiang, Hanash, Samir, DePinho, Ronald A., Draetta, Giulio F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661074/
https://www.ncbi.nlm.nih.gov/pubmed/30918400
http://dx.doi.org/10.1038/s41586-019-1062-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661074/
https://www.ncbi.nlm.nih.gov/pubmed/30918400
http://dx.doi.org/10.1038/s41586-019-1062-1

Ejemplares similares